Faculty Opinions recommendation of Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-.

Author(s):  
Gabriella Scarlatti ◽  
Simone Pensieroso
2011 ◽  
Vol 208 (1) ◽  
pp. 67-80 ◽  
Author(s):  
Daniel O. Griffin ◽  
Nichol E. Holodick ◽  
Thomas L. Rothstein

B1 cells differ in many ways from conventional B cells, most prominently in the production of natural immunoglobulin, which is vitally important for protection against pathogens. B1 cells have also been implicated in the pathogenesis of autoimmune dyscrasias and malignant diseases. It has been impossible to accurately study B1 cells during health and illness because the nature of human B1 cells has not been successfully defined. This has produced controversy regarding the existence of human B1 cells. Here, we determined the phenotype of human B1 cells by testing sort-purified B cell fractions for three fundamental B1 cell functions based on mouse studies: spontaneous IgM secretion, efficient T cell stimulation, and tonic intracellular signaling. We found that a small population of CD20+CD27+CD43+ cells present in both umbilical cord and adult peripheral blood fulfilled these criteria and expressed a skewed B cell receptor repertoire. These B cells express little or no surface CD69 and CD70, both of which are markedly up-regulated after activation of CD20+CD27−CD43− (naive) and CD20+CD27+CD43− (memory) B cells. This work identifies human B1 cells as CD20+CD27+CD43+CD70−. We determined that the proportion of B1 cells declines with age, which may contribute to disease susceptibility. Identification of human B1 cells provides a foundation for future studies on the nature and role of these cells in human disease.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
L. Herrera ◽  
S. Santos ◽  
M. A. Vesga ◽  
J. Anguita ◽  
I. Martin-Ruiz ◽  
...  

AbstractAmong hematological cancers, Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) are the most common leukemia in children and elderly people respectively. Some patients do not respond to chemotherapy treatments and it is necessary to complement it with immunotherapy-based treatments such as chimeric antigen receptor (CAR) therapy, which is one of the newest and more effective treatments against these cancers and B-cell lymphoma. Although complete remission results are promising, CAR T cell therapy presents still some risks for the patients, including cytokine release syndrome (CRS) and neurotoxicity. We proposed a different immune cell source for CAR therapy that might prevent these side effects while efficiently targeting malignant cells. NK cells from different sources are a promising vehicle for CAR therapy, as they do not cause graft versus host disease (GvHD) in allogenic therapies and they are prompt to attack cancer cells without prior sensitization. We studied the efficacy of NK cells from adult peripheral blood (AB) and umbilical cord blood (CB) against different target cells in order to determine the best source for CAR therapy. AB CAR-NK cells are slightly better at killing CD19 presenting target cells and CB NK cells are easier to stimulate and they have more stable number from donor to donor. We conclude that CAR-NK cells from both sources have their advantages to be an alternative and safer candidate for CAR therapy.


Cytokine ◽  
2012 ◽  
Vol 58 (1) ◽  
pp. 40-46 ◽  
Author(s):  
Yu-Han Chen ◽  
Ming-Ling Kuo ◽  
Po-Jen Cheng ◽  
Hsiu-Shan Hsaio ◽  
Pei-Tzu Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document